Why OAC Warns Against Compounded GLP-1 Medications
by Joe Nadglowski, OAC President and CEO For the past 20 years, the Obesity Action Coalition (OAC) has advocated for evidence-based treatments for the disease of obesity. In 2010, OAC began challenging the FDA to take serious action in approving new medicines for obesity treatment. Fast forward to today, and you see we now have
Read Article